Resources Repository
-
ReviewPublication 2004Decision Analysis Applications in Operations Research
This article reviews trends and developments in decision analysis applications, based primarily on a survey of …
This article reviews trends and developments in decision analysis applications, based primarily on a survey of decision analysis applications published in the period 1990–2001 in major English-language operations research and closely related journals. It serves as a guide to those interested in recent applications in specific areas or in applications that illustrate the use of particular methods. The authors identify and discuss noteworthy trends in, and developments affecting, published applications, including those in computer software and…
Operations Research | Decision Analysis | Health/Medicine | Business/Industry -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Technology Assessment | Health/Medicine | Climate/Environment | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Energy/Engineering | Government/Law | North America -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | North America -
ReviewPublication 2021Review of Web-Based Tools for Value-of-Information Analysis
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial …
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial design, and provide information for decisions about reimbursement. The authors review existing web-based tools to facilitate VOI calculations. These include Sheffield Accelerated Value of Information (SAVI), the web interface to the BCEA (Bayesian Cost-Effectiveness Analysis) R package (BCEAweb), Rapid Assessment of Need for Evidence (RANE), and Value of Information for Cardiovascular Trials and Other Comparative Research (VICTOR).
Cost-Effectiveness Analysis | Health/Medicine | Decision Theory | Priority Setting/Ethics | Value of Information | Economics/Finance -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | North America -
ToolInteractive 2020COVID-19 Antibody Tests: Calculator for Interpreting Test Results
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article below* on antibody testing for SARS-CoV-2 virus, allows users to vary the prior probability of infection, the sensitivity of SARS-CoV-2 antibody testing, and the specificity of SARS-CoV-2 antibody testing. Key points made in the article accompanying the interactive include: (1) antibody testing is likely to be most useful 2 weeks after infection, (2) sensitivity and specificity will vary over time and…
Technology Assessment | Health/Medicine | Probability/Bayes | Test Performance | Infectious Diseases | Clinical Care | Science/Technology -
ToolInteractive, Teaching Resource 2020RAND Critical Care Surge Response Tool
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) …
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) to examine the current critical care capacity in the nation’s hospitals and rapidly explore strategies for increasing capacity to provide care for the sickest COVID-19 patients. The tool was developed by the RAND Corporation in response to the 2020 COVID-19 pandemic. Model input parameters to the Excel spreadsheet include baseline number of beds, critical care doctors and nurses, respiratory therapists,…
Operations Research | Health/Medicine | Priority Setting/Ethics | Mathematical Models | Infectious Diseases | North America | Professional | Policy Translation -
ReviewPublication 2018Equity Considerations in CEA: Rotavirus Vaccine in LMIC's
The authors used a systematic review of the literature to identify economic evaluations of rotavirus …
The authors used a systematic review of the literature to identify economic evaluations of rotavirus vaccine in LMICs and assess the extent to which equity was considered in the objectives, analysis, and results. They used equity-related indicators provided in the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria resulting in 18 unique indicators tracked. The authors found that some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented…
Cost-Effectiveness Analysis | Health/Medicine | Evidence Synthesis | Infectious Diseases | Social Determinants | Global -
ReviewPublication 2018Patient Variability Seldom Assessed in Cost-Effectiveness Studies
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether …
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether each cost-effectiveness analysis (CEA) study reported subgroup results and collected data on the defining characteristics of these subgroups. Since estimates can vary across patient subgroups when characteristics are influenced by preferences, outcome risks, treatment effectiveness, life expectancy, or associated costs it can be important to track and report these differences. The authors identified whether any of the CEA subgroup results…
Cost-Effectiveness Analysis | Health/Medicine | Preferences/Values | Social Determinants | Health Systems | Policy/Regulation | Global